Research programme: subtype-selective NMDA receptor modulators - Cadent Therapeutics

Drug Profile

Research programme: subtype-selective NMDA receptor modulators - Cadent Therapeutics

Latest Information Update: 24 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jubilant Pharmaceuticals; Mnemosyne Pharmaceuticals
  • Developer Cadent Therapeutics; Luc Therapeutics
  • Class Neuropsychotherapeutics; Small molecules
  • Mechanism of Action NMDA receptor modulators; NR2B N-Methyl D-Aspartate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Schizophrenia
  • No development reported Alzheimer's disease; Attention-deficit hyperactivity disorder; Brain injuries; Stroke

Most Recent Events

  • 17 Oct 2017 Cadent Therapeutics plans a phase I trial for schizophrenia in 2018
  • 17 Oct 2017 Luc Therapeutics is now called Cadent Therapeutics
  • 06 Mar 2017 Research programme for schizophrenia is underway
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top